| Code | CSB-MP023989HU |
| Abbreviation | Recombinant Human TNFSF13 protein (Active) |
| MSDS | |
| Size | $138 |
| Order now | |
| Image |
|
| Have Questions? | Leave a Message or Start an on-line Chat |
APRIL (TNFSF13) plays a central role in B cell survival and plasma cell differentiation by engaging BCMA (TNFRSF17) and TACI (TNFRSF13B), making it a key target in autoimmune disease and multiple myeloma research. This mammalian-expressed protein, spanning the full-length mature sequence (aa 105–250 of isoform alpha), demonstrates robust receptor binding with an EC50 of 0.8083–0.9391 ng/mL for human BCMA and 11.13–18.97 ng/mL for cynomolgus TACI, providing quantitative benchmarks for cell-based functional assays including B cell proliferation, plasma cell differentiation, and NF-κB signaling pathway activation studies. The low-nanogram potency supports dose-response experiments in primary human PBMCs and B cell lines, while cross-reactivity with cynomolgus TACI enables translational studies in non-human primate models of systemic lupus erythematosus or antibody-mediated rejection. Endotoxin levels below 1.0 EU/μg and purity exceeding 90% meet the quality thresholds commonly required for immune cell assays where LPS contamination would confound cytokine-specific responses.
There are currently no reviews for this product.